Phaseline

Targets › PDE3A

PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A): drug programs, companies and trials

29 programs from 28 companies in 67 trials: 33 Phase 2, 13 Phase 3, 13 Phase 4, 8 Phase 1; Cardiovascular, Other, Genitourinary; next expected readout Nov 2026.

Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. (UniProt, Q14432)

Open in Phaseline: the race on PDE3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
St Joseph University, Beirut, LebanonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Lumbar RadiculopathyDec 2026
Ottawa Heart Institute Research CorporationMilrinone
Phosphodiesterase 3A inhibitor
PDE3APhase 4Shock, CardiogenicDec 2026
Seoul National University Bundang HospitalCilostazol
Phosphodiesterase 3A inhibitor
PDE3APhase 4Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); Type 2 Diabets MellitusDec 2026
VA Office of Research and DevelopmentPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Diabetic Kidney DiseaseJan 2028
Vastra Gotaland RegionDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 4Takotsubo SyndromeDec 2028
Massachusetts General HospitalTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 4PHP IaApr 2030
Zagazig UniversityMilrinone
Phosphodiesterase 3A inhibitor
PDE3APhase 4Pulmonary Hypertension Due to Left Heart Disease–
Beijing Tiantan HospitalY-4 tablets
Integrin alpha-IIb/beta-3 inhibitor
PDE3A, ITGB3, ITGA2B, IL1R1Phase 3Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute …Dec 2026
Al-Azhar UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Chronic Kidney DiseasesDec 2026
Tanta UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3IBS - Irritable Bowel Syndrome; Rheumatoid ArthritisMay 2027
NICHD Neonatal Research NetworkMilrinone
Phosphodiesterase 3A inhibitor
PDE3APhase 3Post-ligation Cardiac SyndromeJun 2027
Tenax TherapeuticsLevosimendan (TNX-103)
Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator
PDE3A, PDE3B, TNNC1, TNNI3, TNNT2Phase 3Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic ShockJun 2028
Merck & Co. (MSD)Ensifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 3Pulmonary Disease, Chronic ObstructiveApr 2029
University of WashingtonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Medication-related Osteonecrosis of the Jaw–
Beni-Suef Universitypentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Embryo Transfer–
Vanderbilt University Medical CenterTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2PseudohypoparathyroidismDec 2026
Mostafa BahaaPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2EpilepsyDec 2026
Yunfeng XiaDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2Restless Leg Syndrome Due to UraemiaDec 2026
Ihab Elsayed HassanPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Inflammatory Bowel DiseasesJan 2027
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEnsifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis BronchiectasisMar 2027
Beni-Suef UniversityAminophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Acute Calculous Anuria; Pediatric Urolithiasis; Renal StonesMar 2027
University Hospital, LimogesPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Medication-related Osteonecrosis of the Jaw (MRONJ)Apr 2027
MediciNovaIbudilast (MN-166)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Amyotrophic Lateral SclerosisApr 2027
Stanford UniversityDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2HypophosphatemiaMay 2027
Montreal Heart InstituteMilrinone
Phosphodiesterase 3A inhibitor
PDE3APhase 2Right Heart FailureMay 2028
M.D. Anderson Cancer CenterPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Lymphedema; Fibrosis SyndromeMay 2029
University Health Network, TorontoPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Non-Small Cell Lung CancerNov 2031
Medical College of WisconsinTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 1Acute Kidney InjuryMay 2027

Conditions

Pseudohypoparathyroidism (2) Stroke Acute (2) Alcohol Use Disorder (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Pulmonary Hypertension Due to Left Heart Disease (2) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Amyotrophic Lateral Sclerosis (1) Hypophosphatemia (1) Epilepsy (1) Pulmonary Hypertension Associated With HFpEF (1)

Modalities

small molecule (29)

Companies

Beni-Suef University (2) University of Washington (1) University Hospital, Limoges (1) MediciNova (1) Stanford University (1) Mostafa Bahaa (1) Tenax Therapeutics (1) M.D. Anderson Cancer Center (1) Seoul National University Bundang Hospital (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) NICHD Neonatal Research Network (1) Ihab Elsayed Hassan (1) Montreal Heart Institute (1) Vanderbilt University Medical Center (1) Beijing Tiantan Hospital (1) University of Pennsylvania (1) Ottawa Heart Institute Research Corporation (1) Al-Azhar University (1)

Related targets

PDE4A (22) PDE5A (14) ADORA2B (11) ADORA2A (11) PDE4D (8) PDE4B (8) PDE4C (8) SLC29A1 (3) PDE6H (3) PDE3B (1) TNNC1 (1) TNNI3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.